Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
January 10, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration...
New Logo.png
Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal’s Activity Against Gram-Positive Bacteria
January 10, 2022 06:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on a formulation of the Company’s pharmaceutical-grade rose bengal against...
Logo.png
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
January 06, 2022 08:00 ET | Cocrystal Pharma, Inc.
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP)...
PB Logo (1).png
Pardes Biosciences to Present at J.P. Morgan Healthcare Conference
January 05, 2022 07:00 ET | Pardes Biosciences, Inc
CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
December 27, 2021 07:00 ET | Pardes Biosciences, Inc
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million,...
PardesBiosciences.png
Pardes Biosciences Appoints New Chief Business and Strategy Officer
November 30, 2021 07:00 ET | Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...
New Designers Space Introduces the VForce Collection: When Technology Meets Fashion
November 11, 2021 09:00 ET | New Designers Space
LOS ANGELES, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Los Angeles-based company, New Designers Space, has recognized the need for wearable technology to keep women and men safe & stylish. The...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET | Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Logo - RBT.jpg
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
October 28, 2021 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
PardesBiosciences.png
Pardes Bioscience Announces Issuance of Its First U.S. Patent
September 21, 2021 16:05 ET | Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new...